Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation
July 22 2013 - 8:00AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories
Holdings, Ltd. (collectively, "Forest") announced today that they
have entered into a settlement agreement with Amerigen
Pharmaceuticals, Inc. and Amerigen Pharmaceuticals, Ltd.
(collectively, "Amerigen") in patent infringement litigation
brought by Forest in response to Amerigen's abbreviated new drug
application (ANDA) seeking approval to market generic versions of
Forest's BYSTOLIC® (nebivolol) tablets. This settlement agreement
is in addition to the previously announced BYSTOLIC® patent
infringement settlement agreements with Hetero Labs Ltd., Alkem
Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd., Torrent
Pharmaceuticals Ltd, and Glenmark Pharmaceuticals Ltd.
Specifically, under the terms of the settlement agreement and
subject to review of the settlement terms by the U.S. Federal Trade
Commission, Forest will provide a license to Amerigen that will
permit it to launch its generic versions of BYSTOLIC® as of the
date that is the later of (a) three calendar months prior to the
expiration of U.S. Patent No. 6,545,040, including any extensions
and/or pediatric exclusivities or (b) the date Amerigen receives
final FDA approval of its ANDA, or earlier in certain
circumstances.
Similar patent infringement litigation brought by Forest against
Actavis, Inc., and related companies and subsidiaries thereof,
remains pending in a multidistrict litigation established in the
U.S. District Court for the Northern District of Illinois.
About Forest
Laboratories
Forest Laboratories' (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory,
gastrointestinal and pain management medicine. Forest’s pipeline,
the most robust in its history, includes product candidates in all
stages of development across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more, visit
www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Forest Laboratories, Inc.Frank J. Murdolo, 1-212-224-6714Vice
President - Investor Relationsmedia.relations@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2023 to Aug 2024